CLINICAL_TRIALS ClinicalTrials.gov record update

Perioperative Retlirafusp Alfa（Anti-PD-L1/TGF-β Bifunctional Fusion Protein） Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial: H-FROG Feasibility Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07847710
Title field or adapter rule: {'original_value': 'Perioperative Retlirafusp Alfa（Anti-PD-L1/TGF-β Bifunctional Fusion Protein） Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial: H-FROG Feasibility Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:31.815568+00:00
Published At: 2026-10-28T00:00:00+00:00
Record Updated At: 2026-10-28
Source Retrieved At: 2026-10-31T22:18:32.315169+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Intrahepatic Cholangiocarcinoma (Icc)", "Neoadjuvant Therapy"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-28", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07847710"
protocolSection.identificationModule.officialTitle: "Perioperative Retlirafusp Alfa\uff08Anti-PD-L1/TGF-\u03b2 Bifunctional Fusion Protein\uff09 Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial: H-FROG Feasibility Study"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Combined treatment group'], 'description': '30 mg/kg, i.v., q3w, Day 3 of each 3-week cycle.', 'name': 'Retlirafusp alfa', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combined treatment group'], 'description': '10 mg, orally, once daily.', 'name': 'Famitinib malate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combined treatment group'], 'description': 'hepatic arterial infusion, Day 1 of each 3-week cycle.', 'name': 'Gemcitabine & oxaliplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combined treatment group'], 'description': '1250 mg/m², orally twice daily, Days 1-14 of each 3-week cycle, as postoperative adjuvant therapy.', 'name': 'Capecitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combined treatment group'], 'description': '40 mg/m², orally twice daily, Days 1-28 of each 6-week cycle, as postoperative adjuvant therapy.', 'name': 'S-1', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combined treatment group'], 'description': 'Hepatic arterial infusion chemotherapy with gemcitabine and oxaliplatin administered on Day 1 of each 3-week cycle.', 'name': 'hepatic arterial infusion chemotherapy (HAIC)', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.